- Home
- OKUR
as 04-18-2025 1:40pm EST
Stocks
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 76.6M | IPO Year: | N/A |
| Target Price: | $32.25 | AVG Volume (30 days): | 49.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.57 - $20.00 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ONKURE THERAPEUTICS INC News
OKUR Breaking Stock News: Dive into OKUR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?
GlobeNewswire
a month ago
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
2 months ago
OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences
GlobeNewswire
4 months ago
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
GlobeNewswire
5 months ago
OnKure Announces New Date for Upcoming Investor Call
GlobeNewswire
5 months ago
OnKure to Present at the Stifel 2024 Healthcare Conference
GlobeNewswire
6 months ago
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
Compare OKUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OKUR ONKURE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.